Cargando…
An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases
The CSF-470 vaccine (VACCIMEL) plus BCG and GM-CSF as adjuvants has been assayed in cutaneous melanoma patients. In the adjuvant randomized Phase II study CASVAC-0401, vaccinated patients had longer distant metastasis-free survival (DMFS) than those treated with IFNα2b. Five years after locking the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011367/ https://www.ncbi.nlm.nih.gov/pubmed/35432383 http://dx.doi.org/10.3389/fimmu.2022.842555 |
_version_ | 1784687674560348160 |
---|---|
author | Mordoh, Ana Aris, Mariana Carri, Ibel Bravo, Alicia Inés Podaza, Enrique Pardo, Juan Carlos Triviño Cueto, Gerardo Rubén Barrio, María Marcela Mordoh, José |
author_facet | Mordoh, Ana Aris, Mariana Carri, Ibel Bravo, Alicia Inés Podaza, Enrique Pardo, Juan Carlos Triviño Cueto, Gerardo Rubén Barrio, María Marcela Mordoh, José |
author_sort | Mordoh, Ana |
collection | PubMed |
description | The CSF-470 vaccine (VACCIMEL) plus BCG and GM-CSF as adjuvants has been assayed in cutaneous melanoma patients. In the adjuvant randomized Phase II study CASVAC-0401, vaccinated patients had longer distant metastasis-free survival (DMFS) than those treated with IFNα2b. Five years after locking the data, an actualization was performed. The benefit in DMFS was maintained in the vaccinated group versus the IFNα2b-treated group (p = 0.035), with a median DMFS of 96 months for VACCIMEL and 13 months for IFNα2b. The favorable risk–benefit ratio was maintained. DMFS was also analyzed as a single cohort in all the IIB, IIC, and III patients (n = 30) who had been treated with VACCIMEL. The median DMFS was 169 months, and at 48 months follow-up, it was 71.4%, which was not statistically different from DMFS of previously published results obtained in adjuvancy with ipilimumab, pembrolizumab, nivolumab, or dabrafenib/trametinib. The possible toxicity of combining VACCIMEL with anti-immune checkpoint inhibitors (ICKi) was analyzed, especially since VACCIMEL was co-adjuvated with BCG in every vaccination. A patient with in-transit metastases was studied to produce a proof of concept. During treatment with VACCIMEL, the patient developed T-cell clones reactive towards tumor-associated antigens. Three years after ending the VACCIMEL study, the patient progressed and was treated with ICKi. During ICKi treatment, the patient did not reveal any toxicity due to previous BCG treatment. When she recurred after a 4-year treatment with nivolumab, a biopsy was obtained and immunohistochemistry and RNA-seq were performed. The tumor maintained expression of tumor-associated antigens and HLA-I and immune infiltration, with immunoreactive and immunosuppressive features. VACCIMEL plus BCG and GM-CSF is an effective treatment in adjuvancy for stages IIB, IIC, and III cutaneous melanoma patients, and it is compatible with subsequent treatments with ICKi. |
format | Online Article Text |
id | pubmed-9011367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90113672022-04-16 An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases Mordoh, Ana Aris, Mariana Carri, Ibel Bravo, Alicia Inés Podaza, Enrique Pardo, Juan Carlos Triviño Cueto, Gerardo Rubén Barrio, María Marcela Mordoh, José Front Immunol Immunology The CSF-470 vaccine (VACCIMEL) plus BCG and GM-CSF as adjuvants has been assayed in cutaneous melanoma patients. In the adjuvant randomized Phase II study CASVAC-0401, vaccinated patients had longer distant metastasis-free survival (DMFS) than those treated with IFNα2b. Five years after locking the data, an actualization was performed. The benefit in DMFS was maintained in the vaccinated group versus the IFNα2b-treated group (p = 0.035), with a median DMFS of 96 months for VACCIMEL and 13 months for IFNα2b. The favorable risk–benefit ratio was maintained. DMFS was also analyzed as a single cohort in all the IIB, IIC, and III patients (n = 30) who had been treated with VACCIMEL. The median DMFS was 169 months, and at 48 months follow-up, it was 71.4%, which was not statistically different from DMFS of previously published results obtained in adjuvancy with ipilimumab, pembrolizumab, nivolumab, or dabrafenib/trametinib. The possible toxicity of combining VACCIMEL with anti-immune checkpoint inhibitors (ICKi) was analyzed, especially since VACCIMEL was co-adjuvated with BCG in every vaccination. A patient with in-transit metastases was studied to produce a proof of concept. During treatment with VACCIMEL, the patient developed T-cell clones reactive towards tumor-associated antigens. Three years after ending the VACCIMEL study, the patient progressed and was treated with ICKi. During ICKi treatment, the patient did not reveal any toxicity due to previous BCG treatment. When she recurred after a 4-year treatment with nivolumab, a biopsy was obtained and immunohistochemistry and RNA-seq were performed. The tumor maintained expression of tumor-associated antigens and HLA-I and immune infiltration, with immunoreactive and immunosuppressive features. VACCIMEL plus BCG and GM-CSF is an effective treatment in adjuvancy for stages IIB, IIC, and III cutaneous melanoma patients, and it is compatible with subsequent treatments with ICKi. Frontiers Media S.A. 2022-04-01 /pmc/articles/PMC9011367/ /pubmed/35432383 http://dx.doi.org/10.3389/fimmu.2022.842555 Text en Copyright © 2022 Mordoh, Aris, Carri, Bravo, Podaza, Pardo, Cueto, Barrio and Mordoh https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Mordoh, Ana Aris, Mariana Carri, Ibel Bravo, Alicia Inés Podaza, Enrique Pardo, Juan Carlos Triviño Cueto, Gerardo Rubén Barrio, María Marcela Mordoh, José An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases |
title | An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases |
title_full | An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases |
title_fullStr | An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases |
title_full_unstemmed | An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases |
title_short | An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases |
title_sort | update of cutaneous melanoma patients treated in adjuvancy with the allogeneic melanoma vaccine vaccimel and presentation of a selected case report with in-transit metastases |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011367/ https://www.ncbi.nlm.nih.gov/pubmed/35432383 http://dx.doi.org/10.3389/fimmu.2022.842555 |
work_keys_str_mv | AT mordohana anupdateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT arismariana anupdateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT carriibel anupdateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT bravoaliciaines anupdateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT podazaenrique anupdateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT pardojuancarlostrivino anupdateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT cuetogerardoruben anupdateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT barriomariamarcela anupdateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT mordohjose anupdateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT mordohana updateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT arismariana updateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT carriibel updateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT bravoaliciaines updateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT podazaenrique updateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT pardojuancarlostrivino updateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT cuetogerardoruben updateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT barriomariamarcela updateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases AT mordohjose updateofcutaneousmelanomapatientstreatedinadjuvancywiththeallogeneicmelanomavaccinevaccimelandpresentationofaselectedcasereportwithintransitmetastases |